| $385M | ||
| $350M | ||
| $215M | ||
| $100M | ||
| $83M | ||
| $63M |
Buys | $1,499,988 | 3 | 75 |
Sells | $1,624,000 | 1 | 25 |
| Bios Equity COF, LP | 1 | $499,996 | 0 | $0 | $499,996 | |
| Fletcher Aaron G.L. | 1 | $499,996 | 0 | $0 | $499,996 | |
| Kreis Leslie W. | 1 | $499,996 | 0 | $0 | $499,996 | |
| THOMSON TODD S | 0 | $0 | 1 | $1.62M | $-1.62M |
Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.
Over the last 12 months, insiders at Actuate Therapeutics Inc have bought $1.5M and sold $1.62M worth of Actuate Therapeutics Inc stock.
On average, over the past 5 years, insiders at Actuate Therapeutics Inc have bought $1.5M and sold $1.62M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Bios Equity COF, LP () — $499,996. Fletcher Aaron G.L. () — $499,996. Kreis Leslie W. () — $499,996.
The last purchase of 71,428 shares for transaction amount of $499,996 was made by Kreis Leslie W. () on 2025‑06‑27.
| 2026-01-05 | Sale | THOMSON TODD S | 280,000 1.0405% | $5.80 | $1.62M | -40.69% | ||
| 2025-06-27 | Kreis Leslie W. | 71,428 0.3203% | $7.00 | $499,996 | +7.05% | |||
| 2025-06-27 | Fletcher Aaron G.L. | 71,428 0.3203% | $7.00 | $499,996 | +7.05% | |||
| 2025-06-27 | Bios Equity COF, LP | 71,428 0.3203% | $7.00 | $499,996 | +7.05% | |||
| 2009-08-27 | Sale | BEITZEL GEORGE B | director | 20,000 0.0738% | $5.76 | $115,120 | ||
| 2009-08-26 | Sale | BEITZEL GEORGE B | director | 40,000 0.1466% | $5.72 | $228,840 | ||
| 2009-05-20 | Sale | PATTERSON ARTHUR C | director | 10,000 0.0322% | $5.02 | $50,223 | ||
| 2007-08-31 | Sale | BEITZEL GEORGE B | director | 50,000 0.2274% | $7.10 | $355,000 | ||
| 2007-08-30 | Sale | BEITZEL GEORGE B | director | 50,000 0.2271% | $7.09 | $354,500 | ||
| 2004-11-24 | Sale | BEITZEL GEORGE B | director | 15,000 0.0232% | $2.41 | $36,150 | ||
| 2004-05-14 | PATTERSON ARTHUR C | director | 20,000 0.0396% | $3.09 | $61,822 | |||
| 2004-05-12 | PATTERSON ARTHUR C | director | 40,000 0.0791% | $3.08 | $123,400 | |||
| 2004-05-10 | PATTERSON ARTHUR C | director | 80,613 0.1608% | $3.11 | $250,990 | |||
| 2004-05-07 | PATTERSON ARTHUR C | director | 17,667 0.036% | $3.18 | $56,122 | |||
| 2004-05-06 | PATTERSON ARTHUR C | director | 14,100 0.0289% | $3.20 | $45,104 | |||
| 2004-05-05 | PATTERSON ARTHUR C | director | 11,500 0.0235% | $3.20 | $36,745 |
| Increased Positions | 29 | +82.86% | 1M | +8.49% |
| Decreased Positions | 14 | -40% | 31,076 | -0.26% |
| New Positions | 7 | New | 98,782 | New |
| Sold Out Positions | 6 | Sold Out | 22,817 | Sold Out |
| Total Postitions | 50 | +42.86% | 13M | +8.23% |